Toxicity and Clinical Trial of Azaserine and 6-Thioguanine in Advanced Solid Malignant Neoplasms by Schroeder, J. M. et al.
449
TOXICITY AND CLINICAL TRIAL OF AZASERINE AND 6-THIO-
GUANINE IN ADVANCED SOLID MALIGNANT NEOPLASMS
J. M. SCHROEDER,* F. J. ANSFIELD,* A. R. CURRERI,* AND G. A. LEPAGEt
From the *Cancer Research Hospital, Madison, Wisconsin, and the
tStanford Research Institute, Palo Alto, California, U.S.A.
Received for publication March 13, 1964
AZASERINE alone was found to be ineffective in a limited spectrum of human
solid tumors, except for short term improvement in 5 out of 44 trials in
Hodgkin's disease (Ellison et al., 1954). Six-thioguanine used alone in leukemia
was found to be somewhat more toxic and less effective than 6-mercaptopurine
(Hales et al., 1957).
Somewhat later Bethel et al. (1960) found little difference in the effectiveness of
6-mercaptopurine and 6-thioguanine. Some advantage has been found in the
combination of azaserine and 6-thioguanine when used in the treatment of mouse
mammary carcinoma (Tarnowski and Stock, 1957).
The structurely similar compound, 6-mercaptopurine, has been used in combina-
tion with azaserine in the treatment of human leukemias (Burchenal et al., 1955;
Hall et al., 1955; Burchenal and Krakoff, 1956; Burchenal, Murphy and Tan,
1956). A careful co-operative evaluation of the combination revealed no advan-
tage over the use of 6-mercaptopurine alone (Heyn et al., 1960).
The mechanism ofaction of 6-thioguanine is different from that of 6-mercapto-
purine (LePage and Jones, 1961). It has been shown that 6-thioguanine is
incorporated into nucleic acids of sensitive cell lines (LePage, 1960), while this
correlation is absent in the case of 6-mercaptopurine.
In addition, Henderson and Junga (1960) found that a 6-thioguanine resistant
subline of Ehrlich carcinoma was not completely resistant to 6-mercaptopurine.
It has been shown that azaserine will cause essentially complete inhibition of
the de novo purine synthesis in sensitive tumor cells (Greenlees and LePage, 1956).
It has been further demonstrated that there is a greater utilization of preformed
purines (for the synthesis of essential nucleic acid) in neoplastic cell lines resistant
to inhibition by azaserine. Since a compound was being sought to exploit the
dependence of certain cell lines on the preformed pathway to purine synthesis
made necessary by the blockade of the de novo pathway by azaserine, 6-thiogua-
nine seemed to be a desirable choice.
The decision to place the combination of 6-thioguanine and azaserine into
clinical trial was based on the encouraging results (Sartorelli and LePage, 1958)
obtained by one of us in the treatment of Ehrlich ascites cell tumors in Swiss mice
by this combination. These studies indicated that the survival times of animals
treated with an appropriate combination of azaserine and 6-thioguanine were
markedly prolonged as compared to the survival times of animals treated with
either agent alone, even in larger doses. This was accomplished with minimal
side effects. It has been shown that concurrent administration of azaserine and450 J. M. SCHROEDER, F. J. ANSFIELD, A. R. CURRERI AND G. A. LePAGE
6-thioguanine will block the de novo and preformed pathways ofpurine nucleotide
synthesis.
It was felt that the studies mentioned above were sufficiently definitive and
encouraging to warrant clinical trial of the combination of agents without further
study ofeach agent alone. It should he noted that the objective was to find a more
effective method of chemotherapy of advanced neoplasms as promptly as possible
and secondarily, to corroborate the finding ofthe effectiveness ofthis combination
in lower animals. It did not seem justifiable to use these agents individually since
the animal data indicated the method chosen was significantly superior.
METHOD
The trial was divided into a toxicity phase (Phase I) and a phase ofpreliminary
clinical evaluation (Phase II).
All the patients included in both the toxicity and the clinical evaluation phases
ofthis study were known to have malignant neoplastic disease. This was defined
by the interpretation by our pathology department ofbiopsy material obtained at
some stage ofthepatient's disease. Often this consisted ofa biopsy atthe original
diagnosis and the finding of a tumor in an organ usually involved in metastatic
disease. Before patients were accepted for inclusion in this study they had been
given benefit of conventional forms of therapy appropriate to the stage of their
disease.
Phase I
The objective of this phase was the determination of the maximum tolerated
dose given over a 7-day period. During Phase I the drugs were administered in
equal amounts and the dose of each was divided into two doses a day. The dose
was started at 0-4 mg./kg. b.i.d. in the first patient and was increased in a stepwise
fashion in each succeeding patient after the previous patient had been followed for
one month. White blood counts were obtained daily during the course oftherapy
and every other day for at least two weeks following the cessation of therapy.
Hemoglobin and weight were obtained at weekly intervals during the therapy and
at the beginning of each new course of therapy. Depending upon the findings of
the initial studies other laboratory studies were obtained as indicated.
Phase II
Phase II studies were designed to demonstrate any therapeutic effects in a
spectrum ofneoplasms. The patients included in this phase suffered from lesions
that could be evaluated by some objective criteria such as direct measurement of
superficial lesions or measurement of deep-seated lesions on the X-ray films.
Patients included in this phase of the investigation were evaluated at regular
intervals-one month after the last dose of the preceding course. Hematologic
and other studies were done as outlined in Phase I, above. A patient was classified
as having showed improvement by the following criteria, each ofwhich must have
been present for a minimum oftwo months (only patients who received 3 4 mg./kg.
of each drug divided into two daily doses for 5 or more consecutive days were
considered to show improvement if the following criteria were met):
1. Reductioninthe size ofa measurable lesion (whichreduction must have been
present for at least two months). Superficial lesions which could not be measuredTRIAL OF AZASERINE AND 6-THIOGUANINE
were photographed in color with a special camera allowing precise duplication of
the reduction ratio and area included in the photograph. These were evaluated
by viewing successive evaluation photographs by placing several small viewers
side by side. Lesions which could be evaluated by X-ray were evaluated by a
special panel of experienced radiologists.*
2. The absence of subjective deterioration as reported by the patient after
recovery from the initial toxic phases of the therapy.
3. Reversal or leveling of a previously downward weight curve if present.
4. Status quo or improvement in performance status. The performance
status at each visit was evaluated as follows:
A. Able to carry on normal activities with no more than some effort.
B. Unable to work, but able to live at home and able to care for most
personal needs with only occasional assistance.
C. Hospitalization necessary; active supportive therapy often neces-
sary.
Administration
The drugs were given intravenously in order to avoid any uncertainties arising
from possible degradation of the drugs in the stomach or other causes of incom-
plete or irregular absorption. They were given twice a day, since it has been
shown (Fernandes, LePage and Lindner, 1956) that azaserine will inhibit the
incorporation of labeled guanine into nucleic acids forabout twelve hours. It has
been demonstrated (Sartorelli and LePage, 1958) that the maximum effectiveness
ofa combination ofazaserine and 6-thioguanine in prolonging the survival time of
tumor-bearing mice was obtained when the drugs were given simultaneously and
twice a day.
Patients included in Phase II of this investigation received 3-4 mg./kg./day
ofeach drug intravenously, divided into two doses a day for 5 days or more. The
drug was administered on the basis of actual body weight unless the patient was
over normal weight. In this case the drug was given on the basis of ideal body
weight as determined from standard age-weight-height-sex tables.
A 100 c.c. syringe was used for the administration of the thioguanine and a
5 c.c. syringe for the azaserine. A three-way stop cock was attached to the two
syringes and a short piece of polyethylene tubing was interposed between the
three-way stop cock and the 22-gauge needle which was used to canulate the vein.
The azaserine was given first, followed by the 6-thioguanine. The material was
administered as rapidly as convenient with the large syringe.
RESULTS
Toxicity phase (Phase I)
Ten different patients participated in this phase of the study. The age and
sex distribution of the sample was unremarkable as may be seen in Table I.
Table II summarizes the types of reactions noted and the various dose levels
at which they occurred. Because of leukopenia, thrombocytopenia, and the less
significant side reactions, it became evident that a dosage level of 3-4 mg./kg./day
* Doctors Pinson Neal, John Juhl, and Lester Paul, of the Department of Radiology of the
University of Wisconsin Medical School.
451452 J. M. SCHROEDER, F. J. ANSFIELD, A. R. CURRERI AND G. A. LePAGE
TABLE I.-Age and Sex of Patients Included in the Toxicity Evaluation
(Phase I)
Age
40-49 . 2 Females 7
50-69 . 6 Males . 3
over 70 2
Total . 10 Total . 10
of each drug divided into two daily doses for 5 to 9 days was the maximum that
could be conveniently tolerated.
A repeat course of therapy was instituted one month after last dose of the
previous course. Patients were considered to beincompletely evaluated untilthey
had received at least two such courses oftherapy, and an evaluation made thirty
days after the last dose of the second course.
TABLE II.-Occurrence* of Side Reactions with Increasingly Larger Doses of
Azaserine and 6-Thioguanine
Each drug was given twice a day at the dose indicated. They were
administered immediately sequentially.
Dose in mg./kg.
0 4 0 5 0-6 0-8 1.0 1-2 1-3 1-4 1-5 1-7
Side reactions
Nausea 1 1 -
Stomatitis . 4 1 - 11
Leukopenia . 1 4
Thrombocytopenia. - - 3
Alopecia - - 1 4
Dermatitis . 2 -
Diarrhea --1
Number of courses. 1 1 1 1 6 2 1 2 3 9
Total different patients: 10
Total courses: 27
* Number of courses of treatment during which this sign or symptom was manifest.
The side reactions observed with the administration of these agents may be
categorized as oral, gastro-intestinal, dermatological and hematological. The
oral manifestations were characterized by a beefy red glossitis and stomatitis.
This is in contra-distinction to the type of stomatitis which has been observed
with the administration of the fluorinated pyrimidines, where a superficial
ulcerating necrotic lesion occurs. The gastro-intestinal symptoms tended to be
considerably more mild at these dosages than those seen with the fluorinated
pyrimidines. Diarrhea was almost never seen, but moderate degrees of anorexia
were very commonly present with occasional nausea or vomiting. Dermatological
changes occurred somewhat more frequently with this combination of agents and
took a number offorms; frequently a diffuse erythema occurring on the legs was
seen. The hematological changes will be described in more detail when discussing
the results in those patients often receiving what we now consider to be thera-
peutic doses. Leukopenia was observed more frequently when larger doses were
used in slightly debilitated patients. Thrombocytopenia occurred, but only
after several months of treatment. The leukopenia occurred primarily in theTRIAL OF AZASERINE AND 6-THIOGUANINE4
mature granulocytes, resulting in a relative lymphocytosis. There did not appear
to be anysignificant alteration intheredblood cells. Temporaryalopeciaoccurred
in a large proportion of patients receiving 3-4 mg./kg./day of each drug divided
into two daily doses.
Preliminary clinical evaluation (Phase II)
In the remarks which follow, it is realized that the numbers ofpatients in each
category are very small and the ideas expressed below are offered more as a sugges-
tion for areas to be investigated further rather than representing firm conclusions
which can be gathered from the present data.
The age and sex distribution ofpatients included in this phase may be seen in
Table III.
Table IVillustrates the clinical results obtained by treatment with 3 4mg./kg./
day of each drug divided into two daily doses for 5 days or longer.
Four out ofseven women treated for carcinoma ofthe breast improved and the
only patient treated for squamous cell carcinoma of the lip improved. Only one
patient was treated in each of the other categories.
TABLE I11.-Clinical Results of Therapy with Azaserine and 6-Thioguanine
The agents were given simultaneously. 3-4 mg./kg./day ofeach agent was
given intravenously for 5 or more days, divided into 2 daily doses.
Age
18-39
40-49
50-69
70 and over
Total
Improved
1
2
3
0
6
Sex
Male
Female
Complications existing on admiission
Ascites
Anemiat
None
Previous chemotherapy
None
Had previous chemotherapy.
Site of spread
Local
Skin
Liver
Lung
Bone
Nodes
Toxic sign
Alopecia
Stomatitis
Leukopeniat
Thrombocytopenia§
Dermatitis.
Other
Unimproved
*
(1) 2
(0) 0
(4) 6
(1) 2
10
(4) 7
(2) 3
(0) 1
(1) 2
(4) 7
1
5
0
0
6
3
3
5
0
0
0
0
1
5
4
1
2
0
1
* Number of patients expected in this group.
t Hb below 9 g./100 c.c.
t WBC less than 2,000/c.mm.
§ Platelet count less than 150,000/c.mm.
(5) 8
(1) 2
(0) 0
(3) 5
(1) 2
(2) 4
(2) 3
(1) 2
(5) 9
(4) 7
(1) 3
(0) 1
(1) 2
(1) 3
Total
3
2
9
2
16
8
8
1
2
13
11
B
5
5
2
4
3
3
14
11
4
3
2
4
453454 J. M. SCHROEDER, F. J. ANSFIELD, A. R. CURRERI AND G. A. LePAGE
TABLE IV.-Clinical Results of Treatment of Various Types of Neoplasms with
Azaserine and 6-Thioguanine
Improved Unimproved Total
Adenocarcinoma
Breast 4 3 7
Cecum . O 1 1
AMucoepidernloid 0 1 1
Rectum 0 1 1
Ovarv . . 0 1 . 1
Squamous cell carcinoma
Lip I . 0
Larynx. I) 1 1
Carcinoma of the lung. 0 1 1
Leiomyosarcoma O) 1 1
Fibrosarcoma. . 0 1 1
Total . 5 11 16
The agents were given simultaneously. 3-4 mg./kg./day or more of each agent was given intra-
venously for 5 or more days divided into 2 (loses each (lay.
The only death due to toxicity in the series occurred on the second course in a
patient who suffered from a mucoepidermoid carcinoma of salivary gland origin.
He had had surgical excision ofthe primary tumor followed four months later by a
radical neck dissection. He received 15,000 r to the tumor from external irradia-
tion and 8000 r by needle implants. This man received 8- days of treatment on
the first course and developed awhite blood count ofas low as 250. The subsequent
course was reduced to six days and his white blood count dropped to 200 and
platelet count dropped to 130,000. The only objective sign of toxicity was the
leukopenia; however, the patient was very weak and at the time of death the
white blood count was 8-0. At autopsy bronchopneumonia with abscess formation
was found as well as cerebral edema not due to trauma or tumor.
Factors which might be thought to influence the results of treatment are also
summarized in Table III. There was no marked difference in the age distribution
in the improved and unimproved groups from that ofthe whole group. There was
a slight preponderance offemales showing improvement, but this may be accounted
for on the basis ofthegood results obtained in carcinoma ofthe breast in the female.
(No males suffering from carcinoma of the breast were treated.) There was no
marked difference in the outcome of therapy depending upon the metastatic site
with the exception of local spread; these patients responded more favorably.
We have felt for some time that it was necessary to produce moderately severe
toxicity with drugs of this class in order to obtain an anti-cancer effect. Some
support for this impression is gained from increased frequency of side reactions
observed in patients showing improvement. However, this may not be true of
this treatment since data on experimental tumors (Sartorelli and LePage, 1958)
show that full anti-tumor effect can be obtained with doses that produced no
toxicity in the host.
Patients listed (Table V) as having had previous chemotherapy (usually
5-fluorouracil) were in relapse after successful therapy of varying duration. The
data suggest that patients who have responded to previous chemotherapy may
respond somewhat more favorably to the combination under study than those
who have not. This would tend to support the concept that certain tumors are
basically sensitive to anti-metabolites and may be sensitive to a variety of agents.TRIAL OF AZASERINE AND 6-THIOGUANINE
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Special mention should be made of thrombocytopenia, a complication which
became evident only after a series of courses. Of the nine patients who received
3-4 mg./kg./day of each drug divided into two daily doses for six days or more on
more than three occasions, four had thrombocytopenia (less than 150,000 per cubic
millimetre). Another patient was reported to have had melena after she left the
hospital and another suffered what was thought to be a cerebral-vascular accident.
Unfortunately, no autopsy was obtained in this case so that a cerebral metastasis
cannot be ruled out. In our judgment, the hemorrhagic manifestations were
common enough to warrant the abandonment of the dose level of 3-4 mg./kg./day
of each drug divided into two daily doses for five days or more. It appears that
if successive courses of therapy are given at intervals of 28 days between the last
dose ofone course and the beginning ofthe next, thrombocytopenia will supervene
in almost all patients in three months. This may not be severe in every patient,
but it reached proportions which we felt made it necessary to stop treatment in all
patients in a period of four months treatment.
Further, it was our experience that ifthe period between courses were increased
to about six weeks in order to allow the thrombocyte count to reach normal levels
and remain there for a period before starting therapy, the malignant lesion tended
to grow rather rapidly and escaped from control, whereas previously, patients
had been held in good remission. Even when the course was re-instituted at
intervals as long as six weeks between courses, the thrombocytopenia tended to
return after rather brief courses of therapy.
SUMMARY
Ten patients were included in a toxicity study (Phase I) of the combination of
azaserine and 6-thioguanine. The maximum tolerated dose was found to be
3.4 mg./kg./day of each agent given intravenously in divided doses twice daily for
five to seven days. This dose was used thereafter.
Sixteen patients were treated at this dose in the early clinical evaluation
(Phase II) of this combination of agents. Of these, one died of toxicity. Four
out of seven patients suffering from carcinoma of the breast, and the one patient
who had a squamous cell carcinoma of the lip, showed improvement; the other
eleven cases were considered unimproved. Three out of six patients treated for
more than three courses developed thrombocytopenia. Other side reactions were:
alopecia (frequently total), glossitis, stomatitis, anorexia, nausea, occasional
vomiting, and dermatitis.
The effectiveness in carcinoma of the breast in this very small series was
encouraging. It is felt that another dose schedule should be employed in an
attempt to circumnavigate the serious thrombocytopenia while preserving
therapeutic effectiveness.
This study was supported by CA-02859, National Cancer Institute, Public
Health Service and the Mrs. Kathryn Pollock Bartlett Memorial.
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APPENDIX
Drug Preparation and Standardization
Azaserine
This material was supplied as a white powder by the Parke-Davis Company
or through the Cancer Chemotherapy National Service Center of the National
Cancer Institute from supplies obtained from the Parke-Davis Company. The
dry powder was kept in a desiccator and in a deep freeze. The drug was prepared
at a concentration of 25 mg./ml. in 0-85 per cent NaCl solution as supplied by the
hospital for intravenous infusion. After dissolving the drug, the solution was
filtered by vacuum, through a sterile ultrafine fritted glass filter into previously
sterilized brown serum vials, which were capped with sterile multipuncture rubber
caps and the material was stored in the deep freeze until used. After preparation
the concentration was checked by making a 1: 10,000 dilution with distilled water
and determining the ultra violet absorption at 2505 m,u on a Beckman DU spectro-
photometer. The extinction for 25 mg./ml./cm. of original solution is 0-284.
The actual concentration of the solution was marked on the label and the drug
was administered on that basis. Spot checks of the sterility of the finished
product were made and it was invariably found to be sterile. Since the material
is an antibiotic in itself, no preservative was added. The concentration of azase-
rine in the vials in storage was checked at random intervals, but no significant loss
of potency was noted.
Thioguanine
The 6-thioguanine used in these studies was initially synthesized by one of us
(G. A. L.) and later was supplied by the Cancer Chemotherapy National Service
Center of the National Cancer Institute from material largely supplied by the
Wellcome Laboratories. This material was dissolved in 0-85 per cent NaCl
solution as supplied by the hospital for intravenous infusion. The calculated
quantity of thioguanine was dissolved in about 80 per cent of the volume required
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up to 7 per cent excess for losses which apparently occurred in filtration. Later,
however, this was found to be unnecessary. Four equivalents of NaOH (10 per
cent solution) for each equivalent weight of 6-thioguanine were added to the NaCl
solution resulting in a pH of 12 or greater. About two hours of constant stirring
were required to effect solution. The pH was then adjusted to 9-5 using 2 N HCI
and a Beckman Model G pH meter. The material was then diluted to volume
with 0-85 per cent NaCl and was passed through a sterile asbestos filter (Seitz
filter) with filter paper beneath the asbestos pad into previously prepared 1 liter
infusion bottles. This was accomplished by using a large bell jar placed on a
vacuum plate allowing the filtration to occur with the assistance of atmospheric
pressure. The concentration ofthe end product was checked by making a 1: 100
dilution of the sample, acidified with about 0.1 ml. of 2 N HC1 per 100 c.c. of the
diluted solution (resulting in a pH of 3 or less) and determining the optical density
at 345 m/t. A concentration of 1 mg./ml./cm. gives an optical density of 1.111
at 345 m,u. The actual concentration ofthe material was indicated on the label of
the container and this concentration was used as the basis for the administration
ofthe prescribed dose. The final preparation was frequently tested and found to
be sterile. It was not possible to await results ofbacteriologic testing before using
the preparations since a precipitate tended to form in two to several days. The
cause ofthe variability in the length oftime required for the material to come out
of solution was never discovered although it appeared that there was considerable
difference in the various batches of the starting material we received. Later
batches tended to be more stable. The concentration of the 6-thioguanine in the
storage bottles was determined frequently and if it was found to be below 80 per
cent of the original value, the material was discarded. (It was found that a pH
of 9-5 was approximately optimum for keeping the drug in solution and yet pre-
venting toorapid deterioration ofthe drug. Ittook about 8 hoursto effect solution
ofthe thioguanine at that pH, and, therefore, the initial solution was made in more
alkaline media.)